CRL vs IQV: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
CRL and IQV are similarly sized, but IQV trades noticeably cheaper on forward earnings (16.29x vs 18.86x): the market is paying up for CRL's profile and pricing IQV more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
CRL vs IQV: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | CRL | IQV | What it tells you |
|---|---|---|---|
| Forward P/E | 18.86 | 16.29 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.40 | 1.20 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 90% of range | 83% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 3.81 | 6.27 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: IQV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how CRL and IQV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CRL and IQV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CRL and IQV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Charles River Laboratories International (CRL) do?
Charles River Laboratories International, Inc. is a leading global contract research organization that helps pharmaceutical and biotech companies discover, develop, and safely test new drugs. It runs three reporting segments: Research Models and Services (RMS), which breeds and supplies purpose-bred lab animals and related services; Discovery and Safety Assessment (DSA), its largest segment, which runs toxicology and safety-testing studies that drugs must pass before human trials; and Manufacturing Solutions, which provides quality-control testing for biologics, cell and gene therapies, and other products. Charles River says it has supported a large majority of the drugs approved by the FDA in recent years, which underlines how embedded it is in the industry's R&D pipeline.
What does IQVIA Holdings (IQV) do?
IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). It operates in three segments: Technology & Analytics Solutions, which sells prescription and market data, real-world evidence, and commercial software to drug and device makers; Research & Development Solutions, its clinical research organization arm that designs and runs clinical trials on behalf of pharma and biotech sponsors; and Contract Sales & Medical Solutions. IQVIA makes money from long-duration trial contracts, recurring data and software subscriptions, and consulting, serving essentially all of the top 20 global pharmaceutical companies.
CRL vs IQV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- CRL drivers: Biopharma R&D demand recovery; Activist-driven strategic review.
- IQV drivers: Record backlog and bookings momentum; Proprietary data and analytics moat.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. For IQV, iQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings.
CRL or IQV: which should you pick?
CRL vs IQV: the full fundamentals
CRL. All figures here are approximate and tied to the asOf date; verify live numbers on a current quote page or the latest SEC filing before acting. CRL is a services company, so its value depends on biopharma R&D demand, execution on cost savings, and the outcome of the strategic review, not on any single commodity price. Valuation multiples are more meaningful here than for a cyclical producer, but they still swing with where the demand cycle sits.
IQV. IQVIA reported full-year 2025 revenue of about $16.3 billion with adjusted diluted EPS near $11.92, and issued 2026 revenue guidance of roughly $17.15 to $17.35 billion alongside adjusted EPS guidance of about $12.55 to $12.85. At a mid-2026 share price near $208 and a market cap around $35 billion, the stock traded at a P/E in the high teens to about 20x, a valuation that has compressed from prior years. The record backlog of about $34.2 billion provides visibility, but the pace of backlog-to-revenue conversion and biotech funding trends drive how much of that guidance is realized.
Headline figures (approximate, Jul 2026): CRL shows revenue trend Roughly flat to slightly up recently, with quarterly revenue around the $1 billion mark; annual revenue in the multi-billion range. Figures are approximate, verify live., profitability Profitable on an adjusted basis; GAAP earnings have been pressured by soft DSA demand and restructuring, with a cost-savings program aimed at protecting margins., balance sheet Carries acquisition-related debt; management has prioritized deleveraging and disciplined capital allocation. Confirm current leverage on the latest filing., market cap tier Mid-cap. Approximate figure has been in the several-billion-dollar range, well below its historical peak. Verify the live number.; IQV shows revenue (fy2025) ~$16.3 billion, adjusted diluted eps (fy2025) ~$11.92, adjusted ebitda (fy2025) ~$3.8 billion, backlog (q1 2026) ~$34.2 billion.
The bottom line: CRL vs IQV
CRL and IQV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CRL and IQV exposure against your real portfolio. It is not an investment adviser.
Wondering how CRL or IQV fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Charles River Laboratories International with AI
Connect the broker you already use and ask Walnut's AI how CRL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between CRL and IQV?
+
Charles River Laboratories International, Inc. IQVIA Holdings is a healthcare-focused data, analytics, and clinical-research company formed in 2016 from the merger of Quintiles (a large CRO) and IMS Health (a pharmaceutical-data provider). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is CRL or IQV the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, CRL or IQV?
+
On forward P/E (as of August 2026), CRL trades at 18.86x and IQV at 16.29x, so IQV is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both CRL and IQV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of CRL vs IQV?
+
CRL: The central risk is demand cyclicality: Charles River's results depend on biopharma R&D budgets, which contracted during the recent biotech funding downturn and can weaken again if capital markets tighten or large clients cut spending. Client concentration and the lumpiness of large study bookings add volatility to any given quarter. The activist strategic review is a double-edged sword: it could unlock value, but the outcome, timing, and any divestitures are uncertain and may disappoint. Regulatory and reputational scrutiny around animal research, plus a long-term industry shift toward non-animal testing methods, could pressure the RMS segment over time. The company also carries debt from past acquisitions, so a prolonged demand slump would weigh on cash flow and flexibility. Competition from other large CROs on price and capacity is persistent. IQV: IQVIA's demand is tied to pharma and biotech R&D budgets, which are cyclical: biopharma funding fell about 20 percent in 2025 to roughly $82 billion as IPOs hit a decade low, and prolonged funding weakness can slow trial starts, RFP flow, and bookings. Large pharma patent cliffs, pricing pressure, and policy changes around drug spending can prompt clients to delay or cancel programs. The company also carries a substantial debt load that it refinances at higher coupons in a higher-for-longer rate environment, which pressures free cash flow and limits strategic flexibility. Competition from ICON and Labcorp in clinical research and Veeva Systems in commercial software is intensifying, and any misstep in converting the large backlog into recognized revenue would weigh on results.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CRL or IQV; figures are approximate and dated (as of August 2026). Verify current data before investing.